These chimeric nanovesicles provide advantages versus existing CDN delivery technologies in 1) the supply of broad‐spectrum tumor antigen complexes for dual T‐cell activation; 2) the cytosolic delivery of STING agonists for enhanced antigen presentation; and 3) the brilliant BBB‐crossing capacity. The gene discussed is STING1; the disease is neoplasm.